This webinar is put on by the International Association for the Study of Lung Cancer
Janet Freeman-Daily will lead the discussion and Q&A, following panel presentations by Dr. Bellinda King-Kallimanis (LUNGevity), Anne Loeser (PCDI, Patient Centered Dosing Initiative), Janice Cowden (PCDI), and Lee Jones (Patient Research Advocate).
- Discover how drug makers have traditionally determined the dose for cancer drugs during early clinical trials
- Find out how the FDA is planning to optimize the calculation of the dose for cancer drugs in the era of targeted therapies
- Hear about the potential impact that patient experience data could have in optimizing the dose
- Learn about the role patient research advocates can play in these discussions